SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Prior treatment

• Previous or co-existing malignancies.
• Received systemic anticancer treatments 4 weeks prior to the initiation of the study treatment.
• Treated with TOP1 inhibitors or ADCs with TOP1 inhibitors as payload.
• Unresolved CTCAE ≥grade 2 toxicities from previous anticancer therapy.

Other illness

• Current or History of ILD.
• Clinical symptoms or diseases of the heart that are not well controlled.
• Arterial/venous thrombosis events occurred before the first dose.
• Grade ≥2 bleeding events of CTCAE occurred before the first dose.
• Gastrointestinal perforation or fistula, urethral fistula, abdominal abscess occurred before the first dose.
• Serious infection before the first dose.
• Active hepatitis B or active hepatitis C.
• History of severe hypersensitivity reactions to either the drug substances or inactive ingredients of SHR-A1921.

Other

• Uncontrolled pleural effusion, pericardial effusion, or abdominal effusion with clinical symptoms.
• Patients with intestinal obstruction or parenteral nutrition before the first dose.
• Other inappropriate situation considered by the investigator.

• Voluntary participation and written informed consent.
• 18 years and older, female.
• Pathologically diagnosed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
• Patients must have platinum-resistant disease
• Be able to provide fresh or archived tumour tissue.
• At least one measurable lesion according to RECIST v1.1.
• Eastern Cooperative Oncology Group (ECOG) score: 0-1.
• With a life expectancy ≥ 12 weeks.
• Adequate bone marrow reserve and organ function.
• Contraception is required during the trial.